R
Rallybio Corp (RLYB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$15.29
-0.13 (-0.88%)
Market Cap: $88.03M
Last updated: Nov 17, 2026 at 4:15 PM ET
Rallybio Corp (RLYB) Valuation Multiples
Rallybio (RLYB) trades at 201.3x sales and 0.9x book value. Its P/B of 0.9x is below its 5-year median of 1.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 201.3x |
| Price to book | 0.9x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 0.9x | 1.0x | N/A |
Valuation History
Over the 3 of the 5 year ends shown that have a P/S, its P/S ranged from 35.3x in 2025 to 426.0x in 2023.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $5.49 | 35.3x | 0.5x |
| 2024 | $7.68 | 67.0x | 0.7x |
| 2023 | $19.12 | 426.0x | 0.9x |
| 2022 | $52.56 | N/A | 1.4x |
| 2021 | $76.32 | N/A | 1.6x |
Frequently Asked Questions About RLYB
What is RLYB's price to sales ratio?
Rallybio has a price to sales ratio of 201.3x.
RLYB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors